Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Pancreas development in humans

Pan, Fong Chenga; Brissova, Marcelab

Current Opinion in Endocrinology & Diabetes and Obesity: April 2014 - Volume 21 - Issue 2 - p 77–82
doi: 10.1097/MED.0000000000000047
DIABETES AND THE ENDOCRINE PANCREAS I: Edited by David M. Harlan
Buy

Purpose of review We highlight some of the major recent advances in characterizing human pancreas development and endocrine cell differentiation.

Recent findings Extensive research efforts have helped to define crucial events in the mouse pancreas organogenesis. Information gained from these studies was used to develop human embryonic stem cell (hESC) differentiation protocols with the goal of generating functional glucose-responsive, insulin-producing human β-cells. In spite of remarkable progress in hESC differentiation, current protocols based on mouse developmental biology can produce human β-cells only in vivo. New differentiation markers and recently generated reagents may provide an unprecedented opportunity to develop a high-density expression map of human fetal pancreas and pancreatic islets that could serve as a reference point for in vitro hESC differentiation.

Summary Integrating an increased knowledge of human pancreas development into hESC differentiation protocols has the potential to greatly advance our ability to generate functional insulin-producing cells for β-cell replacement therapy.

aDepartment of Cell and Developmental Biology and Vanderbilt University Program in Developmental Biology

bDivision of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA

Correspondence to Marcela Brissova, PhD, Vanderbilt University, Department of Medicine, Division of Diabetes, Endocrinology, and Metabolism, 2213 Garland Avenue, 7465 MRB IV, Nashville, TN 37232-0475, USA. Tel: +1 615 936 1729; fax: +1 615 936 1667; e-mail: marcela.brissova@vanderbilt.edu

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins